Repositioning Candidate Details
| Candidate ID: | R0856 |
| Source ID: | DB05736 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MIV-701 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in osteoporosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MIV-701 inhibits an enzyme, cathepsin K, which degrades bone, but most probably also contributes to cartilage damage in joint diseases. It greatly reduces degradation of bone. |
| Targets: | Cathepsin K |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |